A Cost-Effectiveness Analysis of Epoetin Usage for Patients with AIDS

Scott B. Cantor; Richard W. Carson; Stephen J. Spann

doi:10.2165/00019053-199303030-00007

A Cost-Effectiveness Analysis of Epoetin Usage for Patients with AIDS

Scott B. Cantor, Richard W. Carson, Stephen J. Spann

CCSG - Cancer Prevention

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Epoetin (recombinant human erythropoietin) therapy for patients with AIDS may reduce the need for blood transfusion; however, it is expensive. We conducted a cost-effectiveness analysis of the use of epoetin for AIDS patients from a healthcare system perspective. We constructed a decision analysis model using probability. Outcome and cost data from the literature and hospital sources. The incremental cost-effectiveness ratio was measured in dollars per unit of blood saved. In AIDS patients undergoing transfusion with serum epoetin concentrations ⩽500 U/L treatment with epoetin cost $US1007 per unit of blood saved compared with treatment without epoetin. One-way sensitivity analysis revealed that the incremental cost-effectiveness ratio was sensitive 10 the efficacy and unit price of epoetin, but less sensitive to the current price cap determined by the distributor.

Original language	English (US)
Pages (from-to)	244-249
Number of pages	6
Journal	PharmacoEconomics
Volume	3
Issue number	3
DOIs	https://doi.org/10.2165/00019053-199303030-00007
State	Published - Mar 1993

ASJC Scopus subject areas

Pharmacology
Health Policy
Public Health, Environmental and Occupational Health

Access to Document

10.2165/00019053-199303030-00007

Cite this

@article{f993af404254472fac8d32e699706be0,

title = "A Cost-Effectiveness Analysis of Epoetin Usage for Patients with AIDS",

abstract = "Epoetin (recombinant human erythropoietin) therapy for patients with AIDS may reduce the need for blood transfusion; however, it is expensive. We conducted a cost-effectiveness analysis of the use of epoetin for AIDS patients from a healthcare system perspective. We constructed a decision analysis model using probability. Outcome and cost data from the literature and hospital sources. The incremental cost-effectiveness ratio was measured in dollars per unit of blood saved. In AIDS patients undergoing transfusion with serum epoetin concentrations ⩽500 U/L treatment with epoetin cost $US1007 per unit of blood saved compared with treatment without epoetin. One-way sensitivity analysis revealed that the incremental cost-effectiveness ratio was sensitive 10 the efficacy and unit price of epoetin, but less sensitive to the current price cap determined by the distributor.",

author = "Cantor, {Scott B.} and Carson, {Richard W.} and Spann, {Stephen J.}",

year = "1993",

month = mar,

doi = "10.2165/00019053-199303030-00007",

language = "English (US)",

volume = "3",

pages = "244--249",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "3",

}

TY - JOUR

T1 - A Cost-Effectiveness Analysis of Epoetin Usage for Patients with AIDS

AU - Cantor, Scott B.

AU - Carson, Richard W.

AU - Spann, Stephen J.

PY - 1993/3

Y1 - 1993/3

N2 - Epoetin (recombinant human erythropoietin) therapy for patients with AIDS may reduce the need for blood transfusion; however, it is expensive. We conducted a cost-effectiveness analysis of the use of epoetin for AIDS patients from a healthcare system perspective. We constructed a decision analysis model using probability. Outcome and cost data from the literature and hospital sources. The incremental cost-effectiveness ratio was measured in dollars per unit of blood saved. In AIDS patients undergoing transfusion with serum epoetin concentrations ⩽500 U/L treatment with epoetin cost $US1007 per unit of blood saved compared with treatment without epoetin. One-way sensitivity analysis revealed that the incremental cost-effectiveness ratio was sensitive 10 the efficacy and unit price of epoetin, but less sensitive to the current price cap determined by the distributor.

AB - Epoetin (recombinant human erythropoietin) therapy for patients with AIDS may reduce the need for blood transfusion; however, it is expensive. We conducted a cost-effectiveness analysis of the use of epoetin for AIDS patients from a healthcare system perspective. We constructed a decision analysis model using probability. Outcome and cost data from the literature and hospital sources. The incremental cost-effectiveness ratio was measured in dollars per unit of blood saved. In AIDS patients undergoing transfusion with serum epoetin concentrations ⩽500 U/L treatment with epoetin cost $US1007 per unit of blood saved compared with treatment without epoetin. One-way sensitivity analysis revealed that the incremental cost-effectiveness ratio was sensitive 10 the efficacy and unit price of epoetin, but less sensitive to the current price cap determined by the distributor.

UR - http://www.scopus.com/inward/record.url?scp=0027567362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027567362&partnerID=8YFLogxK

U2 - 10.2165/00019053-199303030-00007

DO - 10.2165/00019053-199303030-00007

M3 - Article

C2 - 10146947

AN - SCOPUS:0027567362

SN - 1170-7690

VL - 3

SP - 244

EP - 249

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 3

ER -

A Cost-Effectiveness Analysis of Epoetin Usage for Patients with AIDS

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this